Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases
Abstract
:1. Introduction
2. Sclerostin, a Molecule That Regulates Bone Remodeling
3. Efficacy of Romosozumab in Osteoporotic Women and Men
4. Mechanism of Action of Anti-Sclerostin Antibodies
5. Comparison with Other Anti-Fracture Treatments
5.1. Comparison with Teriparatide
5.2. Comparison with Bisphosphonates
5.3. Comparison with Denosumab
6. Side Effects of Anti-Sclerostin Therapy
6.1. General Adverse Events
6.2. Cardiovascular Risk
7. Transition from Anti-Sclerostin Therapy at Treatment Cessation
8. Anti-Sclerostin Therapy in Other Bone Diseases
9. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Matsuo, K.; Irie, N. Osteoclast-osteoblast communication. Arch. Biochem. Biophys. 2008, 473, 201–209. [Google Scholar] [CrossRef] [PubMed]
- Sims, N.A.; Gooi, J.H. Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin. Cell Dev. Biol. 2008, 19, 444–451. [Google Scholar] [CrossRef] [PubMed]
- Baron, R.; Kneissel, M. WNT signaling in bone homeostasis and disease: From human mutations to treatments. Nat. Med. 2013, 19, 179–192. [Google Scholar] [CrossRef] [PubMed]
- Li, X.; Zhang, Y.; Kang, H.; Liu, W.; Liu, P.; Zhang, J.; Harris, S.E.; Wu, D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 2005, 280, 19883–19887. [Google Scholar] [CrossRef] [Green Version]
- Balemans, W.; Ebeling, M.; Patel, N.; Van Hul, E.; Olson, P.; Dioszegi, M.; Lacza, C.; Wuyts, W.; Van Den Ende, J.; Willems, P.; et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 2001, 10, 537–543. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brunkow, M.E.; Gardner, J.C.; Van Ness, J.; Paeper, B.W.; Kovacevich, B.R.; Proll, S.; Skonier, J.E.; Zhao, L.; Sabo, P.J.; Fu, Y.; et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 2001, 68, 577–589. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Balemans, W.; Patel, N.; Ebeling, M.; Van Hul, E.; Wuyts, W.; Lacza, C.; Dioszegi, M.; Dikkers, F.G.; Hildering, P.; Willems, P.J.; et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 2002, 39, 91–97. [Google Scholar] [CrossRef]
- Staehling-Hampton, K.; Proll, S.; Paeper, B.W.; Zhao, L.; Charmley, P.; Brown, A.; Gardner, J.C.; Galas, D.; Schatzman, R.C.; Beighton, P.; et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet. 2002, 110, 144–152. [Google Scholar] [CrossRef]
- Cosman, F.; Crittenden, D.B.; Adachi, J.D.; Binkley, N.; Czerwinski, E.; Ferrari, S.; Hofbauer, L.C.; Lau, E.; Lewiecki, E.M.; Miyauchi, A.; et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N. Engl. J. Med. 2016, 375, 1532–1543. [Google Scholar] [CrossRef]
- Glorieux, F.H.; Devogelaer, J.-P.; Durigova, M.; Goemaere, S.; Hemsley, S.; Jakob, F.; Junker, U.; Ruckle, J.; Seefried, L.; Winkle, P.J. BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial. J. Bone Miner. Res. 2017, 32, 1496–1504. [Google Scholar] [CrossRef]
- Recker, R.R.; Benson, C.T.; Matsumoto, T.; Bolognese, M.A.; Robins, D.A.; Alam, J.; Chiang, A.Y.; Hu, L.; Krege, J.H.; Sowa, H.; et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J. Bone Miner. Res. 2015, 30, 216–224. [Google Scholar] [CrossRef] [PubMed]
- Glass, D.A.; Bialek, P.; Ahn, J.D.; Starbuck, M.; Patel, M.S.; Clevers, H.; Taketo, M.M.; Long, F.; McMahon, A.P.; Lang, R.A.; et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 2005, 8, 751–764. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kramer, I.; Halleux, C.; Keller, H.; Pegurri, M.; Gooi, J.H.; Weber, P.B.; Feng, J.Q.; Bonewald, L.F.; Kneissel, M. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol. Cell. Biol. 2010, 30, 3071–3085. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Albers, J.; Keller, J.; Baranowsky, A.; Beil, F.T.; Catala-Lehnen, P.; Schulze, J.; Amling, M.; Schinke, T. Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin. J. Cell Biol. 2013, 200, 537–549. [Google Scholar] [CrossRef] [Green Version]
- Weivoda, M.M.; Ruan, M.; Hachfeld, C.M.; Pederson, L.; Howe, A.; Davey, R.A.; Zajac, J.D.; Kobayashi, Y.; Williams, B.O.; Westendorf, J.J.; et al. Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways. J. Bone Miner. Res. 2019, 34, 1546–1548. [Google Scholar] [CrossRef] [Green Version]
- Wei, W.; Zeve, D.; Suh, J.M.; Wang, X.; Du, Y.; Zerwekh, J.E.; Dechow, P.C.; Graff, J.M.; Wan, Y. Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin. Mol. Cell. Biol. 2011, 31, 4706–4719. [Google Scholar] [CrossRef] [Green Version]
- Otero, K.; Shinohara, M.; Zhao, H.; Cella, M.; Gilfillan, S.; Colucci, A.; Faccio, R.; Ross, F.P.; Teitelbaum, S.L.; Takayanagi, H.; et al. TREM2 and β-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J. Immunol. 2012, 188, 2612–2621. [Google Scholar] [CrossRef]
- Poole, K.E.S.; van Bezooijen, R.L.; Loveridge, N.; Hamersma, H.; Papapoulos, S.E.; Löwik, C.W.; Reeve, J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005, 19, 1842–1844. [Google Scholar] [CrossRef] [Green Version]
- Winkler, D.G.; Sutherland, M.K.; Geoghegan, J.C.; Yu, C.; Hayes, T.; Skonier, J.E.; Shpektor, D.; Jonas, M.; Kovacevich, B.R.; Staehling-Hampton, K.; et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003, 22, 6267–6276. [Google Scholar] [CrossRef] [Green Version]
- Van Bezooijen, R.L.; Bronckers, A.L.; Gortzak, R.A.; Hogendoorn, P.C.W.; van der Wee-Pals, L.; Balemans, W.; Oostenbroek, H.J.; Van Hul, W.; Hamersma, H.; Dikkers, F.G.; et al. Sclerostin in mineralized matrices and van Buchem disease. J. Dent. Res. 2009, 88, 569–574. [Google Scholar] [CrossRef]
- Weivoda, M.M.; Youssef, S.J.; Oursler, M.J. Sclerostin expression and functions beyond the osteocyte. Bone 2017, 96, 45–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maeda, K.; Kobayashi, Y.; Koide, M.; Uehara, S.; Okamoto, M.; Ishihara, A.; Kayama, T.; Saito, M.; Marumo, K. The Regulation of Bone Metabolism and Disorders by Wnt Signaling. Int. J. Mol. Sci. 2019, 20, 5525. [Google Scholar] [CrossRef] [Green Version]
- Roforth, M.M.; Fujita, K.; McGregor, U.I.; Kirmani, S.; McCready, L.K.; Peterson, J.M.; Drake, M.T.; Monroe, D.G.; Khosla, S. Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone 2014, 59, 1–6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Padhi, D.; Jang, G.; Stouch, B.; Fang, L.; Posvar, E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 2011, 26, 19–26. [Google Scholar] [CrossRef]
- Cosman, F.; Crittenden, D.B.; Ferrari, S.; Khan, A.; Lane, N.E.; Lippuner, K.; Matsumoto, T.; Milmont, C.E.; Libanati, C.; Grauer, A. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. J. Bone Miner. Res. 2018, 33, 1219–1226. [Google Scholar] [CrossRef]
- McClung, M.R.; Brown, J.P.; Diez-Perez, A.; Resch, H.; Caminis, J.; Meisner, P.; Bolognese, M.A.; Goemaere, S.; Bone, H.G.; Zanchetta, J.R.; et al. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. J. Bone Miner. Res. 2018, 33, 1397–1406. [Google Scholar] [CrossRef]
- Geusens, P.; Oates, M.; Miyauchi, A.; Adachi, J.D.; Lazaretti-Castro, M.; Ebeling, P.R.; Perez Niño, C.A.; Milmont, C.E.; Grauer, A.; Libanati, C. The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study. JBMR Plus 2019, 3, e10211. [Google Scholar] [CrossRef]
- Cosman, F.; Crittenden, D.B.; Ferrari, S.; Lewiecki, E.M.; Jaller-Raad, J.; Zerbini, C.; Milmont, C.E.; Meisner, P.D.; Libanati, C.; Grauer, A. Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. J. Bone Miner. Res. 2018, 33, 1407–1416. [Google Scholar] [CrossRef]
- Ominsky, M.S.; Boyce, R.W.; Li, X.; Ke, H.Z. Effects of sclerostin antibodies in animal models of osteoporosis. Bone 2017, 96, 63–75. [Google Scholar] [CrossRef] [PubMed]
- Chavassieux, P.; Chapurlat, R.; Portero-Muzy, N.; Roux, J.-P.; Garcia, P.; Brown, J.P.; Libanati, C.; Boyce, R.W.; Wang, A.; Grauer, A. Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment. J. Bone Miner. Res. 2019, 34, 1597–1608. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lewiecki, E.M.; Blicharski, T.; Goemaere, S.; Lippuner, K.; Meisner, P.D.; Miller, P.D.; Miyauchi, A.; Maddox, J.; Chen, L.; Horlait, S. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J. Clin. Endocrinol. Metab. 2018, 103, 3183–3193. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, X.; Ominsky, M.S.; Villasenor, K.S.; Niu, Q.-T.; Asuncion, F.J.; Xia, X.; Grisanti, M.; Wronski, T.J.; Simonet, W.S.; Ke, H.Z. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis. Endocrinology 2018, 159, 260–271. [Google Scholar] [CrossRef]
- Ebina, K.; Hirao, M.; Tsuboi, H.; Nagayama, Y.; Kashii, M.; Kaneshiro, S.; Miyama, A.; Nakaya, H.; Kunugiza, Y.; Okamura, G.; et al. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 2020, 140, 115574. [Google Scholar] [CrossRef] [PubMed]
- Ominsky, M.S.; Niu, Q.-T.; Li, C.; Li, X.; Ke, H.Z. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J. Bone Miner. Res. 2014, 29, 1424–1430. [Google Scholar] [CrossRef]
- Frost, H.M. Bone “mass” and the “mechanostat”: A proposal. Anat. Rec. 1987, 219, 1–9. [Google Scholar] [CrossRef]
- Kim, S.W.; Lu, Y.; Williams, E.A.; Lai, F.; Lee, J.Y.; Enishi, T.; Balani, D.H.; Ominsky, M.S.; Ke, H.Z.; Kronenberg, H.M.; et al. Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts. J. Bone Miner. Res. 2016. [Google Scholar] [CrossRef] [PubMed]
- Nioi, P.; Taylor, S.; Hu, R.; Pacheco, E.; He, Y.D.; Hamadeh, H.; Paszty, C.; Pyrah, I.; Ominsky, M.S.; Boyce, R.W. Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats. J. Bone Miner. Res. 2015, 30, 1457–1467. [Google Scholar] [CrossRef] [PubMed]
- Boyce, R.W.; Niu, Q.-T.; Ominsky, M.S. Kinetic reconstruction reveals time-dependent effects of romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys. Bone 2017, 101, 77–87. [Google Scholar] [CrossRef]
- Taylor, S.; Ominsky, M.S.; Hu, R.; Pacheco, E.; He, Y.D.; Brown, D.L.; Aguirre, J.I.; Wronski, T.J.; Buntich, S.; Afshari, C.A.; et al. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. Bone 2016, 84, 148–159. [Google Scholar] [CrossRef] [Green Version]
- Dempster, D.W.; Zhou, H.; Recker, R.R.; Brown, J.P.; Recknor, C.P.; Lewiecki, E.M.; Miller, P.D.; Rao, S.D.; Kendler, D.L.; Lindsay, R.; et al. Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study. J. Bone Miner. Res. 2018, 33, 298–306. [Google Scholar] [CrossRef]
- Dempster, D.W.; Zhou, H.; Ruff, V.A.; Melby, T.E.; Alam, J.; Taylor, K.A. Longitudinal Effects of Teriparatide or Zoledronic Acid on Bone Modeling- and Remodeling-Based Formation in the SHOTZ Study. J. Bone Miner. Res. 2018, 33, 627–633. [Google Scholar] [CrossRef] [Green Version]
- Boyce, R.W.; Brown, D.; Felx, M.; Mellal, N.; Locher, K.; Pyrah, I.; Ominsky, M.S.; Taylor, S. Decreased osteoprogenitor proliferation precedes attenuation of cancellous bone formation in ovariectomized rats treated with sclerostin antibody. Bone Rep. 2018, 8, 90–94. [Google Scholar] [CrossRef] [PubMed]
- Taylor, S.; Hu, R.; Pacheco, E.; Locher, K.; Pyrah, I.; Ominsky, M.S.; Boyce, R.W. Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized rats. Bone Rep. 2018, 8, 95–103. [Google Scholar] [CrossRef] [PubMed]
- Holdsworth, G.; Greenslade, K.; Jose, J.; Stencel, Z.; Kirby, H.; Moore, A.; Ke, H.Z.; Robinson, M.K. Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists. Bone 2018, 107, 93–103. [Google Scholar] [CrossRef] [PubMed]
- Florio, M.; Gunasekaran, K.; Stolina, M.; Li, X.; Liu, L.; Tipton, B.; Salimi-Moosavi, H.; Asuncion, F.J.; Li, C.; Sun, B.; et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat. Commun. 2016, 7. [Google Scholar] [CrossRef] [PubMed]
- McClung, M.R.; Grauer, A.; Boonen, S.; Bolognese, M.A.; Brown, J.P.; Diez-Perez, A.; Langdahl, B.L.; Reginster, J.-Y.; Zanchetta, J.R.; Wasserman, S.M.; et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2014, 370, 412–420. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Langdahl, B.L.; Libanati, C.; Crittenden, D.B.; Bolognese, M.A.; Brown, J.P.; Daizadeh, N.S.; Dokoupilova, E.; Engelke, K.; Finkelstein, J.S.; Genant, H.K.; et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial. Lancet 2017, 390, 1585–1594. [Google Scholar] [CrossRef]
- Wu, J.; Cai, X.-H.; Qin, X.-X.; Liu, Y.-X. The effects of sclerostin antibody plus parathyroid hormone (1–34) on bone formation in ovariectomized rats. Z. Gerontol. Geriatr. 2018, 51, 550–556. [Google Scholar] [CrossRef]
- Saag, K.G.; Petersen, J.; Brandi, M.L.; Karaplis, A.C.; Lorentzon, M.; Thomas, T.; Maddox, J.; Fan, M.; Meisner, P.D.; Grauer, A. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N. Engl. J. Med. 2017, 377, 1417–1427. [Google Scholar] [CrossRef] [Green Version]
- Lau, E.M.C.; Dinavahi, R.; Woo, Y.C.; Wu, C.-H.; Guan, J.; Maddox, J.; Tolman, C.; Yang, W.; Shin, C.S. Romosozumab or alendronate for fracture prevention in East Asian patients: A subanalysis of the phase III, randomized ARCH study. Osteoporos. Int. 2020. [Google Scholar] [CrossRef] [Green Version]
- Asadipooya, K.; Weinstock, A. Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate. Arterioscler. Thromb. Vasc. Biol. 2019, 39, 1343–1350. [Google Scholar] [CrossRef] [PubMed]
- Caffarelli, C.; Montagnani, A.; Nuti, R.; Gonnelli, S. Bisphosphonates, atherosclerosis and vascular calcification: Update and systematic review of clinical studies. Clin. Interv. Aging 2017, 12, 1819–1828. [Google Scholar] [CrossRef] [Green Version]
- Kranenburg, G.; Bartstra, J.W.; Weijmans, M.; de Jong, P.A.; Mali, W.P.; Verhaar, H.J.; Visseren, F.L.J.; Spiering, W. Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis. Atherosclerosis 2016, 252, 106–115. [Google Scholar] [CrossRef] [PubMed]
- Kim, D.H.; Rogers, J.R.; Fulchino, L.A.; Kim, C.A.; Solomon, D.H.; Kim, S.C. Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis. PLoS ONE 2015, 10. [Google Scholar] [CrossRef]
- Pietrzyk, B.; Smertka, M.; Chudek, J. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders. Adv. Clin. Exp. Med. Off. Organ. Wroclaw Med. Univ. 2017, 26, 1283–1291. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Turk, J.R.; Deaton, A.M.; Yin, J.; Stolina, M.; Felx, M.; Boyd, G.; Bienvenu, J.-G.; Varela, A.; Guillot, M.; Holdsworth, G.; et al. Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture. Regul. Toxicol. Pharmacol. 2020, 115, 104697. [Google Scholar] [CrossRef] [PubMed]
- Bovijn, J.; Krebs, K.; Chen, C.-Y.; Boxall, R.; Censin, J.C.; Ferreira, T.; Pulit, S.L.; Glastonbury, C.A.; Laber, S.; Millwood, I.Y.; et al. Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci. Transl. Med. 2020, 12. [Google Scholar] [CrossRef] [PubMed]
- Novo-Rodríguez, C.; García-Fontana, B.; Luna-Del Castillo, J.D.D.; Andújar-Vera, F.; Ávila-Rubio, V.; García-Fontana, C.; Morales-Santana, S.; Rozas-Moreno, P.; Muñoz-Torres, M. Circulating levels of sclerostin are associated with cardiovascular mortality. PLoS ONE 2018, 13, e0199504. [Google Scholar] [CrossRef]
- Lv, F.; Cai, X.; Yang, W.; Gao, L.; Chen, L.; Wu, J.; Ji, L. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis. Bone 2020, 130, 115121. [Google Scholar] [CrossRef]
- Cummings, S.R.; McCulloch, C. Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab. Osteoporos. Int. 2020, 31, 1019–1021. [Google Scholar] [CrossRef] [Green Version]
- Kawaguchi, H. Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide. J. Bone Miner. Res. 2020, 35, 994–995. [Google Scholar] [CrossRef] [PubMed]
- Lewiecki, E.M.; Dinavahi, R.V.; Lazaretti-Castro, M.; Ebeling, P.R.; Adachi, J.D.; Miyauchi, A.; Gielen, E.; Milmont, C.E.; Libanati, C.; Grauer, A. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J. Bone Miner. Res. 2019, 34, 419–428. [Google Scholar] [CrossRef] [PubMed]
- Horne, A.M.; Mihov, B.; Reid, I.R. Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates. Calcif. Tissue Int. 2018, 103, 55–61. [Google Scholar] [CrossRef] [PubMed]
- Kendler, D.L.; Bone, H.G.; Massari, F.; Gielen, E.; Palacios, S.; Maddox, J.; Yan, C.; Yue, S.; Dinavahi, R.V.; Libanati, C.; et al. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos. Int. 2019, 30, 2437–2448. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McClung, M.R.; Bolognese, M.A.; Brown, J.P.; Reginster, J.-Y.; Langdahl, B.L.; Maddox, J.; Shi, Y.; Rojeski, M.; Meisner, P.D.; Grauer, A. A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporos. Int. 2020. [Google Scholar] [CrossRef] [PubMed]
- Cardinal, M.; Dessain, A.; Roels, T.; Lafont, S.; Ominsky, M.S.; Devogelaer, J.-P.; Chappard, D.; Mabilleau, G.; Ammann, P.; Nyssen-Behets, C.; et al. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice. Calcif. Tissue Int. 2020. [Google Scholar] [CrossRef] [PubMed]
- Cardinal, M.; Tys, J.; Roels, T.; Lafont, S.; Ominsky, M.S.; Devogelaer, J.-P.; Chappard, D.; Mabilleau, G.; Ammann, P.; Nyssen-Behets, C.; et al. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta. Bone 2019, 124, 137–147. [Google Scholar] [CrossRef]
- Setrusumab: Dose-Dependent Bone Building & Trend in Fracture Reduction | Mereo BioPharma. Available online: https://www.mereobiopharma.com/news-and-events/press-releases/2019/setrusumab-dose-dependent-bone-building-trend-in-fracture-reduction/setrusumab-dose-dependent-bone-building-trend-in-fracture-reduction/ (accessed on 2 March 2020).
- Seefried, L.; Baumann, J.; Hemsley, S.; Hofmann, C.; Kunstmann, E.; Kiese, B.; Huang, Y.; Chivers, S.; Valentin, M.-A.; Borah, B.; et al. Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. J. Clin. Investig. 2017, 127, 2148–2158. [Google Scholar] [CrossRef] [Green Version]
- Toscani, D.; Bolzoni, M.; Ferretti, M.; Palumbo, C.; Giuliani, N. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy. Front. Immunol. 2018, 9, 2467. [Google Scholar] [CrossRef]
- Hesse, E.; Schröder, S.; Brandt, D.; Pamperin, J.; Saito, H.; Taipaleenmäki, H. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight 2019, 5. [Google Scholar] [CrossRef]
- Appel, H.; Ruiz-Heiland, G.; Listing, J.; Zwerina, J.; Herrmann, M.; Mueller, R.; Haibel, H.; Baraliakos, X.; Hempfing, A.; Rudwaleit, M.; et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009, 60, 3257–3262. [Google Scholar] [CrossRef] [PubMed]
Treatment | Therapeutical Class | Type of Treatment | Effect on Bone Modeling and Remodeling | Overall Bone Formation/Resorption | Ob Number /Activity | Oc Number /Activity |
---|---|---|---|---|---|---|
Alendronate | Bisphosphonate | Anti-resorptive | ↓ remodeling ? modeling | ↓/↓ | ↔/↔ | ↓/↓ |
Denosumab | Anti-RANKL antibody | Anti-resorptive | ↓ remodeling ↔modeling [40] | ↓/↓ | ↔/↔ | ↓/↓ |
Teriparatide | Recombinant human PTH | Anabolic | ↑ remodeling ↑ modeling (transient) [41] | ↑/↑ | ↑/↑ | ↑/↑ |
Romosozumab | Anti-sclerostin antibody | Anabolic | ↑ modeling (transient) ↓ remodeling | ↑ then ↓/↓ | ↑ then ↓/↑ | ↓/↓ |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Fabre, S.; Funck-Brentano, T.; Cohen-Solal, M. Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases. J. Clin. Med. 2020, 9, 3439. https://doi.org/10.3390/jcm9113439
Fabre S, Funck-Brentano T, Cohen-Solal M. Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases. Journal of Clinical Medicine. 2020; 9(11):3439. https://doi.org/10.3390/jcm9113439
Chicago/Turabian StyleFabre, Stéphanie, Thomas Funck-Brentano, and Martine Cohen-Solal. 2020. "Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases" Journal of Clinical Medicine 9, no. 11: 3439. https://doi.org/10.3390/jcm9113439